Gendux Molecular Limited - Development and Commercialization of targeted, molecular medicines for European markets

Latest News

11/27/2007 - Gendux Announces Acceptance of its ADVEXIN Marketing Authorization Application for Review by the EMEA

11/13/2007 - Gendux and Introgen Submit First Marketing Authorization Application for ADVEXIN

4/16/2007 - Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference

Gendux Molecular Limited is a subsidiary of Introgen Therapeutics, Inc. (NASDAQ:INGN), a leader in the field of molecular oncology.

Gendux Molecular Limited ("Gendux") is focused on the commercialization of targeted molecular therapies to be applied with molecular diagnostic tools to introduce personalized medical products in European and other markets. Gendux Molecular Ltd is an Irish company based in Dublin, Ireland and is a subsidiary of Introgen Therapeutics, Inc.

Contact Our Office